# US 2021/0171634 A1 · Anti-lag-3 antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171634 A1
- Document ID: US20210171634A1
- Status: Published application
- Kind: A1
- Application number: 17/100,038
- Filed: 2020-11-20
- Published: 2021-06-10
- Earliest claimed: 2016-10-11
- Assignees: Agenus Inc.
- Applicants: Agenus Inc.
- Inventors: Nicholas Stuart Wilson; David Adam Savitsky; Shawn Michael Jennings; Marc van Dijk; Cornelia Anne Mundt
- Web page: https://patentgrep.com/patent/US20210171634A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 47/6873: {the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody}
- A61P 35/00: Antineoplastic agents
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

## Claims

### Claim at position 1

1-126. (canceled)

### Claim 127

An isolated antibody that specifically binds to human LAG-3, the antibody comprising a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, wherein:
(a) CDRH1 comprises the amino acid sequence of DX1YX2X3 (SEQ ID NO: 140), wherein
X1 is T or N,
X2 is I or M, and
X3 is H, Y or D;
(b) CDRH2 comprises the amino acid sequence of X1IDPANX2X3X4X5X6X7PX8X9QX10 (SEQ ID NO: 142), wherein
X1 is E, R, S, or K,
X2 is D or G,
X3 is N or H,
X4 is T or S,
X5 is K or H,
X6 is Y or F,
X7 is D or A,
X8 is K or R,
X9 is F or L, and
X10 is G or D;
(c) CDRH3 comprises the amino acid sequence of YX1X2X3YX4VGGX5DY (SEQ ID NO: 144), wherein
X1 is Y, F, or S,
X2 is Y or D,
X3 is K or R,
X4 is D or E, and
X5 is F or C;
(d) CDRL1 comprises the amino acid sequence of SVSSX1ISSSX1LX3 (SEQ ID NO: 147), wherein
X1 is S or G,
X2 is N or T, and
X3 is H or Y;
(e) CDRL2 comprises the amino acid sequence of SEQ ID NO: 104; and
(f) CDRL3 comprises the amino acid sequence of QQWX1X2YPX3T (SEQ ID NO: 149), wherein
X1 is S, N, or R,
X2 is S, T or R, and
X3 is F, L, H, or W,
wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 do not comprise the amino acid sequences of SEQ ID NOs: 79, 90, 98, 100, 104, and 105, respectively.

### Claim 128 (depends on 127)

The isolated antibody of claim 127, wherein:
(a) CDRH1 comprises the amino acid sequence of DX1YX2X3 (SEQ ID NO: 141), wherein
X1 is T or N,
X2 is I or M, and
X3 is H or Y;
(b) CDRH2 comprises the amino acid sequence of X1IDPANX2X3X4KX5X6PX7FQX8 (SEQ ID NO: 143), wherein
X1 is E, R, or S,
X2 is D or G,
X3 is N or H,
X4 is T or S,
X5 is Y or F,
X6 is D or A,
X7 is K or R, and
X8 is G or D;
(c) CDRH3 comprises the amino acid sequence of YX1X2X3YDVGGX4DY (SEQ ID NO: 145), wherein
X1 is Y, F, or S,
X2 is Y or D,
X3 is K or R, and
X4 is F or C;
(d) CDRH3 comprises the amino acid sequence of YYYX1YX2VGGFDY (SEQ ID NO: 146), wherein
X1 is K or R, and
X2 is D or E;
(e) CDRL1 comprises the amino acid sequence of SVSSSISSSNLX1 (SEQ ID NO: 148), wherein X1 is H or Y; and/or
(f) CDRL3 comprises the amino acid sequence of QQWX1SYPX2T (SEQ ID NO: 150), wherein
X1 is S, N, or R, and
X2 is F, L, or H.

### Claim 129 (depends on 127)

The isolated antibody of claim 127, wherein:
(a) CDRH1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-82;
(b) CDRH2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 83-93;
(c) CDRH3 comprises the amino acid sequence of YYYX1YX2VGGFDY (SEQ ID NO: 146), wherein
X1 is K or R, and
X2 is D or E;
(d) CDRH3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 94-99;
(e) CDRL1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 100-103; and/or
(f) CDRL3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-112.

### Claim 130 (depends on 127)

The isolated antibody of claim 127, wherein CDRH1, CDRH2 and CDRH3 comprise the CDRH1, CDRH2 and CDRH3 amino acid sequences, respectively, set forth in SEQ ID NOs: 78, 83, and 94; 78, 85, and 95; 78, 86, and 96; 78, 86, and 97; 78, 91, and 94; 78, 92, and 96; 79, 84, and 95; 79, 88, and 95; 79, 89, and 95; 79, 90, and 95; 79, 90, and 98; 79, 90, and 99; 80, 85, and 96; 81, 87, and 96; or, 82, 93, and 95, and/or CDRL1, CDRL2 and CDRL3 comprise the CDRL1, CDRL2 and CDRL3 amino acid sequences, respectively, set forth in SEQ ID NOs: 100, 104, and 105; 100, 104, and 106; 100, 104, and 107; 100, 104, and 109; 100, 104, and 110; 101, 104, and 108; 102, 104, and 105; 102, 104, and 112; or, 103, 104, and 111.

### Claim 131 (depends on 127)

The isolated antibody of claim 127, wherein:
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences set forth in SEQ ID NOs: 78, 83, 94, 100, 104, and 105; 78, 85, 95, 100, 104, and 105; 78, 86, 96, 100, 104, and 105; 78, 86, 96, 100, 104, and 109; 78, 86, 96, 100, 104, and 110; 78, 86, 96, 101, 104, and 108; 78, 86, 96, 103, 104, and 111; 78, 86, 97, 102, 104, and 112; 78, 91, 94, 100, 104, and 107; 78, 92, 96, 100, 104, and 105; 78, 92, 96, 100, 104, and 109; 79, 84, 95, 100, 104, and 105; 79, 84, 95, 100, 104, and 106; 79, 84, 95, 102, 104, and 105; 79, 88, 95, 100, 104, and 105; 79, 89, 95, 100, 104, and 105; 79, 90, 95, 100, 104, and 105; 79, 90, 99, 100, 104, and 105; 80, 85, 96, 100, 104, and 105; 81, 87, 96, 100, 104, and 105; 81, 87, 96, 100, 104, and 107; or 82, 93, 95, 100, 104, and 105, respectively.

### Claim 132 (depends on 127)

The isolated antibody of claim 127, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 151, 222, 218, or 223, and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 152 or 224.

### Claim 133 (depends on 127)

The isolated antibody of claim 127, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence which is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-72 and 220, and/or a light chain variable region comprising an amino acid sequence which is at least 75%, 80%, 85%, 90%, 95%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 73-77 and 221.

### Claim 134 (depends on 127)

The isolated antibody of claim 127, wherein the antibody comprises a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 168-186 and 225-227, and/or a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 187-191 and 228.

### Claim 135 (depends on 127)

The isolated antibody of claim 127, wherein the antibody comprises:
(a) a heavy chain variable framework region that is or is derived from an amino acid sequence encoded by a human gene, optionally wherein said amino acid sequence is selected from the group consisting of IGHV1-46*01 (SEQ ID NO: 153), IGHV1-69-2*01 (SEQ ID NO: 154), IGHV1-3*01 (SEQ ID NO: 155), IGHV1-24*01 (SEQ ID NO: 156), IGHV1-2*01 (SEQ ID NO: 157), IGHV1-45*01 (SEQ ID NO: 158), and IGHV1-18*01 (SEQ ID NO: 159); and/or
(b) a light chain variable framework region that is or is derived from an amino acid sequence encoded by a human gene, optionally wherein said amino acid sequence is selected from the group consisting of IGKV3-20*01 (SEQ ID NO: 160), IGKV3D-15*01 (SEQ ID NO: 161), IGKV3-15*01 (SEQ ID NO: 161), IGKV3D-20*01 (SEQ ID NO: 162), IGKV3D-7*01 (SEQ ID NO: 163), IGKV1-9*01 (SEQ ID NO: 164), and IGKV3-11*01 (SEQ ID NO: 165).

### Claim 136 (depends on 127)

The isolated antibody of claim 127, wherein the antibody comprises:
(a) a heavy chain variable framework region that is derived from the amino acid sequence IGHV1-46*01 (SEQ ID NO: 153), wherein at least one amino acid in the amino acid sequence IGHV1-46*01 (SEQ ID NO: 153) is substituted with an amino acid in an analogous position in a corresponding non-human heavy chain variable framework region, optionally wherein the amino acid substitution is at an amino acid position selected from the group consisting of 4, 5, 12, 23, 27, 28, 29, 30, 48, 69, 71, 75, 76, 80, 81, and 94, further optionally wherein the amino acid substitution is selected from the group consisting of 4M, 5K, 12V, 23T, 27F, 28N, 29I, 30K, 48I, 69I, 71A, 75S, 76N, 80L, 81Q, and 94T; and/or
(b) a light chain variable framework region that is derived from the amino acid sequence IGKV3-20*01 (SEQ ID NO: 160), wherein at least one amino acid in the amino acid sequence IGKV3-20*01 (SEQ ID NO: 160) is substituted with an amino acid in an analogous position in a corresponding non-human light chain variable framework region, optionally wherein the amino acid substitution is at an amino acid position selected from the group consisting of 3, 22, 36, 43, 47, 58, 70, and 71, further optionally wherein the amino acid substitution is selected from the group consisting of 3L, 22T, 36F, 43S, 47W, 58V, 70S, and 71Y,
wherein the position of the amino acid substitution is indicated according to the Kabat numbering system.

### Claim 137 (depends on 127)

The isolated antibody of claim 127, wherein the heavy chain variable region and the light chain variable region, respectively, comprise the amino acid sequences set forth in SEQ ID NOs: 56 and 73; 56 and 74; 56 and 75; 56 and 76; 56 and 77; 57 and 73; 57 and 74; 57 and 75; 57 and 76; 57 and 77; 58 and 73; 58 and 74; 58 and 75; 58 and 76; 58 and 77; 59 and 73; 59 and 74; 59 and 75; 59 and 76; 59 and 77; 60 and 73; 60 and 74; 60 and 75; 60 and 76; 60 and 77; or 62 and 77.

### Claim 138 (depends on 127)

The isolated antibody of claim 127, wherein the antibody comprises:
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 168 or 225, and a light chain comprising the amino acid sequence of SEQ ID NO: 187 or 228;
(b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 169 or 226, and a light chain comprising the amino acid sequence of SEQ ID NO: 187 or 228; or
(c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 169 or 226, and a light chain comprising the amino acid sequence of SEQ ID NO: 187 or 228.

### Claim 139 (depends on 127)

The isolated antibody of claim 127, wherein the antibody comprises a heavy chain constant region selected from the group consisting of human IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2, and optionally wherein the heavy chain constant region is:
(a) an IgG1 heavy chain constant region comprising a N297A mutation, optionally wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 194;
(b) an IgG1 heavy chain constant region comprising a N297Q mutation;
(c) a non-fucosylated IgG1 heavy chain constant region; and/or
(d) an IgG4 heavy chain constant region comprises a S228P mutation, optionally wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 196,
wherein the amino acid residues are numbered according to the EU numbering system.

### Claim 140 (depends on 127)

The isolated antibody of claim 127, wherein the antibody comprises a light chain constant region selected from the group consisting of a human kappa light chain and a human lambda light chain, optionally wherein the light chain constant region is a human kappa light chain constant region comprising the amino acid sequence of SEQ ID NO: 198 or 219.

### Claim 141 (depends on 127)

The isolated antibody of claim 127, wherein the antibody is conjugated to a cytotoxic agent, cytostatic agent, toxin, radionuclide, or detectable label.

### Claim 142 (depends on 127)

A pharmaceutical composition comprising the antibody of claim 127 and a pharmaceutically acceptable carrier or excipient.
